All In Biotech

Drug Trial Radar · NCT04144517

A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer

A Phase 2 Study of ALKS 4230 in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer Currently on Treatment With Anti-PD-(L)1 Without Having Achieved a Complete Remission

Last checked: Nov 19, 2026Latest source record: Oct 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

14

Actual

Start

Feb 5, 2020

Primary completion

Oct 8, 2021

Study completion Jan 7, 2022

Sponsor

Lead sponsor
Mural Oncology, IncIndustry
Sponsor type
Industry
Collaborators
Immune Oncology Network (ION)
First posted
Oct 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to estimate the response rate to ALKS 4230 in combination with pembrolizumab in patients with HNSCC who had previously received anti-PD-(L)1 therapy but who had not achieved a CR.

Conditions

  • Squamous Cell Carcinoma of Head and Neck

Interventions

  • Nemvaleukin AlfaDrug

    Nemvaleukin alfa IV infusion.

  • PembrolizumabDrug

    Pembrolizumab IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) Based on RECIST v1.1Time frame: From the first dose of study drug until first PD or death, whichever occurred first (up to 49 weeks)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Mural Oncology Investigational Site

    Miami, Florida

  • Mural Oncology Investigational Site

    Atlanta, Georgia

  • Mural Oncology Investigational Site

    Minneapolis, Minnesota

  • Mural Oncology Investigational Site

    New York, New York

  • Mural Oncology Investigational Site

    New York, New York

  • Mural Oncology Investigational Site

    Cleveland, Ohio

  • Mural Oncology Investigational Site

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.